Shukra Pharma rescheduled its 33rd Annual General Meeting due to administrative reasons. Book closure dates for the AGM are also revised. All previously announced agenda items and appointments remain unchanged.
Shukra Pharmaceuticals announced a ₹0.01 per share final dividend for FY25-26, pending shareholder approval at the upcoming AGM. A record date is established to determine eligible shareholders.
The board has approved allotting 11.73 lakh equity shares to promoter Navkar Surgical Gujarat Ltd upon warrant conversion, raising ₹3.13 Cr. This boosts paid-up capital from ₹43.96 Cr to ₹44.08 Cr. 17.35 lakh warrants are still outstanding.
